Google Übersetzer
Ascendis Pharma A/s
About
Ascendis Pharma A/s — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
Apr 20 2026
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
Apr 8 2026
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
Apr 6 2026
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
Mar 17 2026
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Recent Videos
Novo's 9,000 — The Companies Hiring Them THIS WEEK 💊📞 #shorts #denmark #novonordisk #jobsearch
Mar 31, 2026
Interview de Carol BRUCKER, Présidente - Directrice Générale Ascendis Pharma FranceBeNeLux
Mar 10, 2026
Ascendis Pharma FDA Approves Once-Weekly YUVIWEL for Children with Achondroplasia Aged 2 Years
Mar 03, 2026
Ascendis Pharma Q4 2025 Earnings Call
Feb 12, 2026